Stmnt re Share Price Movement
Company notes share price movement; reconfirms trading position and FDA De Novo progression.
Select text to share a quote on X · sign in to keep highlights & notes in your GENI notes
Oxford, UK. GENinCode Plc (AIM: GENI), the predictive genetics company focused on the prevention of cardiovascular disease and ovarian cancer, notes the movement in the share price yesterday and again today.
The Company knows no reason for this sudden movement, albeit the board believes the shares remain undervalued. The Company reconfirms its trading and operation position set out in the trading update of 26 August 2025 with FDA De Novo discussions continuing to progress and work ongoing to close out the remaining deficiencies. Collaboration discussions on potential US and EU test distribution are progressing with a major distributer. The Company looks forward to updating the market at its interim results on Tuesday, 30 September 2025.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.